Atorvastatin Price Trend and Forecast 2026-2027

The US paid the most for atorvastatin in Q2 2026: USD 63.0/KG, up 1.9% from USD 61.8 in Q1. The steady generic-statin demand kept things firm there. Worldwide, the average moved up 2.0%, to USD 51.6/KG from USD 50.6, largely because the chiral side-chain feedstock costs kept climbing across every region we track. What about H2 2026? We'd expect a global average somewhere in the USD 51.0-55.5/KG range, with the steady cardiovascular-formulation demand doing most of the work.

Atorvastatin is made from a chiral side-chain intermediate condensed with a diketone intermediate, then crystallized as the calcium salt used in most tablet formulations. It's one of the world's most widely prescribed cholesterol-lowering statins, feeding formulations that treat cardiovascular disease across essentially every major healthcare system. As a long-off-patent generic, its demand tracks population cardiovascular-health needs and the generic-substitution rates more than any single innovation cycle. Three things move the price more than anything else: the chiral side-chain feedstock costs, the generic-formulation demand from pharmaceutical manufacturers, and how much API capacity the producers in India and China are running. That off-patent status also means pricing here reflects a genuinely competitive generic market rather than the pricing power a single patent holder might exercise, which is part of why the quarter-to-quarter moves track feedstock costs so closely rather than showing the kind of pricing discretion a branded pharmaceutical product might display.

The chiral chemistry involved in making this molecule is genuinely more complex than most generic drugs require, and that complexity has real pricing implications. Building the specific stereochemistry atorvastatin needs takes more processing steps than a simpler, non-chiral API would, which is part of why the production has concentrated among a relatively small number of specialized manufacturers capable of running that chemistry efficiently at scale, mostly in India and China. A handful of producers in India and China have built genuine expertise in this specific chemistry over the past two decades, and that accumulated know-how has become almost as important a competitive advantage as raw production capacity.

Because cardiovascular disease is such a widespread, chronic condition across aging populations worldwide, this market tends to show less demand volatility than most pharmaceutical categories. Patients on statin therapy typically stay on it for years, which gives manufacturers and formulators a fairly predictable demand base to plan around, even as the input costs themselves fluctuate quarter to quarter. That predictability has made this market a useful benchmark for buyers comparing volatility across different generic pharmaceutical categories, since few other widely used drug classes show such a stable, chronic-therapy demand base.

Atorvastatin Price Forecast for 2026

Supply and demand should stay moderately tight through H2 2026, with the chiral side-chain feedstock costs doing most of the work on pricing. Germany and the US both kept the generic-formulation demand steady through H1, and that's likely to continue. India's large API base should keep the supply ample even as the domestic and export demand both firm, and none of the four markets we track shows signs of a genuine disruption heading into the back half of the year.

Given how concentrated the chiral-intermediate production is among a handful of specialized manufacturers, any disruption at one of the larger facilities tends to have an outsized effect on pricing relative to what you'd see in a less specialized generic-drug market.

For buyers comparing suppliers across regions, it is worth remembering that pharmaceutical-grade material carries regulatory documentation requirements that go beyond simple purity specifications, and switching suppliers mid-contract can involve real qualification lead times that most industrial chemical buyers never have to consider. Formulators generally need to requalify a new API source through their own regulatory filings before switching, a process that can take months rather than weeks. That lag tends to smooth out short-term price differences between suppliers, since buyers cannot simply chase the cheapest quarter's pricing the way they might with a less regulated commodity.

What could push prices higher? A chiral-intermediate feedstock spike, or a stronger-than-expected surge in generic-statin demand. What could pull them lower? Expanded low-cost Indian or Chinese API capacity outpacing the demand.

For the Quarter Ending June 2026

Atorvastatin Prices Q2 2026:

• India: USD 45.6/KG
• China: USD 39.6/KG
• United States: USD 63.0/KG
• Germany: USD 58.7/KG

Atorvastatin Prices in India

India's atorvastatin producers passed through the firmer chiral-intermediate costs this quarter, and the generic-formulation demand held steady. The gain came to 2.0%, USD 44.7/KG to USD 45.6.

Why did the price of Atorvastatin change in Q2 2026 in India?

The chiral side-chain feedstock costs firmed through the quarter, and the generic-formulation demand held its ground right alongside that.

Atorvastatin Prices in China

China gained 1.8% to USD 39.6/KG, the domestic API demand staying firm even as the feedstock costs climbed.

Why did the price of Atorvastatin change in Q2 2026 in China?

The domestic API demand stayed firm, and the feedstock costs climbed just enough to nudge things higher.

Atorvastatin Prices in United States

USD 63.0/KG. That's where the US landed in Q2, up 1.9% from USD 61.8 in Q1. The formulation demand stayed steady, and the feedstock costs climbed just enough to push things higher.

Why did the price of Atorvastatin change in Q2 2026 in United States?

The formulation demand didn't move much, honestly. It was the feedstock costs doing most of the work this quarter.

Atorvastatin Prices in Germany

Germany gained 2.1% to USD 58.7/KG, the European regulatory-grade demand continuing to hold steady through the period.

Why did the price of Atorvastatin change in Q2 2026 in Germany?

The European regulatory-grade demand held steady, and that alone explains most of the move here.

For the Quarter Ending March 2026

Atorvastatin Prices Q1 2026:

• India: USD 44.7/KG
• China: USD 38.9/KG
• United States: USD 61.8/KG
• Germany: USD 57.5/KG

Atorvastatin Prices in India

India gained 2.1% to USD 44.7/KG, the formulation demand firming as the year opened.

Why did the price of Atorvastatin change in Q1 2026 in India?

The generic-formulation demand firmed as the year opened, and the chiral-intermediate costs edged higher right alongside it.

Atorvastatin Prices in China

China rose 2.1% to USD 38.9/KG, the API demand firming with the new year.

Why did the price of Atorvastatin change in Q1 2026 in China?

The API demand firmed with the new year, and the feedstock costs kept climbing steadily too.

Atorvastatin Prices in United States

US atorvastatin climbed 2.0% to USD 61.8/KG, the formulation demand staying firm through the quarter.

Why did the price of Atorvastatin change in Q1 2026 in United States?

The formulation demand stayed firm, and the feedstock costs firmed alongside it.

Atorvastatin Prices in Germany

Germany gained 2.0% to USD 57.5/KG, the regulatory-grade demand building through the quarter.

Why did the price of Atorvastatin change in Q1 2026 in Germany?

The regulatory-grade demand built through the quarter, tracking the prescription volumes closely.

Quarterly Atorvastatin Price Trends

The global average climbed steadily across the window, from USD 47.5/KG in Q1 2025 to USD 51.6 by Q2 2026, a net gain of about 8.6%. Every quarter posted a gain here, reflecting the firming chiral-intermediate feedstock costs and the steady generic-formulation demand across every market we track, with the pace picking up modestly in the most recent two quarters.

What was Atorvastatin Price in 2025?

2025 was a steadily firming year for atorvastatin. Starting near USD 47.5/KG in Q1, the global average finished 2025 at USD 49.6, a gain of about 4.4%. The chiral-intermediate feedstock costs firmed gradually all year, and the generic-formulation demand held dependable throughout, tracking the steady, predictable rhythm of the underlying cardiovascular-treatment demand.

Atorvastatin Prices in India in 2025

Indian prices moved from about USD 42.0/KG in Q1 2025 to USD 43.8 by Q4, up roughly 4.3%. The generic-formulation demand held steady all year across the country's large API base.

Atorvastatin Prices in China in 2025

Chinese prices climbed from USD 36.5/KG in Q1 to USD 38.1 by Q4, a 4.4% gain, and China stayed the most affordable of the four markets throughout the year.

Atorvastatin Prices in United States in 2025

US prices rose from USD 58.0/KG in Q1 to USD 60.6 by Q4, up 4.5%, the highest absolute price throughout the four markets on the steady formulation demand.

Atorvastatin Prices in Germany in 2025

German prices moved from USD 54.0/KG in Q1 to USD 56.4 by Q4, a 4.4% gain, as the European regulatory-grade demand stayed firm through the year.

How We Can Help

Expert Market Research: Your Source for Real-Time Atorvastatin Price Intelligence

We keep a continuous eye on the atorvastatin prices wherever it's produced or consumed at scale, tracing causation through the chiral side-chain feedstock economics, the generic-formulation demand, and the API capacity utilization across India and China. Our analysts track the specialized chiral-intermediate manufacturers closely, since production there is concentrated enough that a single disruption can move the broader market, and we watch regulatory-filing timelines that can affect how quickly buyers are able to switch between qualified suppliers. Need pricing data, bespoke market analysis, or procurement advisory? Reach out to our team. We also flag any regulatory or manufacturing-site news that could affect supply before it fully shows up in the pricing data.